Disclosed herein are sulfonyl benzamide compounds, and the use thereof in the treatment of bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukmia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T -cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer. In one embodiment the compound is N-({ 4-[(cyclohexylmethyl)amino]-3-nitrophenyl} sulfonyl)-3&rsquo；-{ [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino} biphenyl-4-carboxamide.
